Gilead Sciences, Inc.

- Gilead does not expect to pursue any sizable M&A or meaningful new fundraising through debt or equity in the near term. - The company has about $5 billion in cash and leverage is back to pre-Immunomedics deal levels. - Gilead plans to continue ordinary course licensing deals but not large acquisitions for now. - Capital allocation will remain disciplined with a focus on pipeline investment and shareholder returns. - They generate strong operating cash flow and will be flexible but cautious with capital deployment. - No updates were given indicating any planned equity or debt issuance in the near future.

- Gilead plans to double its manufacturing capacity for cell therapies as part of its expansion plans in the cell therapy franchise. - The company is advancing next-generation CAR-T lymphoma assets quickly, with three constructs in Phase 1a and 1b clinical trials. - They will invest to support the launch of seladelpar (acquired through the CymaBay deal) and other R&D efforts. - Capital allocation priorities remain disciplined with sufficient balance sheet flexibility; no sizable M&A is expected in the near term. - Ordinary course licensing deals will continue, with the company highlighting CymaBay as a model for strategic acquisitions. - Ongoing investments include expanding commercial infrastructure, particularly in liver disease, to ensure seladelpar's successful market introduction. - Gilead emphasizes disciplined expense management alongside investments to support growth and pipeline development.

- Total product sales (excluding Veklury) expected to grow 4% to 6% in 2024, reaching $25.8 to $26.2 billion. - Base business sales projected to grow ~6% year-over-year in 2024. - HIV sales growth forecasted at approximately 4% for 2024, with HIV business expected to be flat in 2025 due to Medicare Part D redesign impact. - Oncology sales up 18% year-over-year in Q1 2024, with multiple Phase 3 trials ongoing for Trodelvy in various tumors, supporting long-term growth. - Liver disease business sales up 9% year-over-year, with seladelpar expected to contribute modestly to sales in 2024 and more meaningfully in 2025 and beyond. - Cell therapy expected to expand through broader indications and manufacturing scale-up, driving future growth. - Overall business expected to grow in 2025 despite some headwinds in HIV. - Gilead plans to maintain disciplined expense management to support margin and earnings growth.

- Full-year 2024 revenue guidance remains unchanged, expecting total product sales of $27.1 to $27.5 billion, representing 4% to 6% growth excluding Veklury. - Diluted EPS guidance updated to $3.45 to $3.85 for 2024, impacted by a nondeductible $4.4 billion acquired IPR&D charge from the CymaBay acquisition. - Excluding acquisition-related charges, non-GAAP EPS is comfortably within prior guidance ranges. - Operating margins are expected to improve over time, supported by disciplined expense management and top-line growth. - In 2025, HIV sales expected to be roughly flat due to Medicare Part D redesign headwinds, but overall business anticipated to grow. - The CymaBay acquisition is expected to be dilutive to EPS in 2024 but breakeven in 2025 and significantly accretive thereafter. - Continued focus on disciplined expense management and capital allocation with potential moderate SG&A increase due to CymaBay integration.

The provided document does not explicitly mention details regarding the current or expected orderbook or pending orders for Gilead Sciences. However, relevant points related to business performance and outlook include: - Total product sales, excluding Veklury, grew 6% year-over-year to $6.1 billion in Q1 2024. - Sales growth driven by higher demand in HIV, oncology, and liver disease. - HIV product sales grew 4% year-over-year; oncology product sales were up 18%. - Veklury sales were $555 million, down 3% year-over-year. - Seladelpar expected to contribute modestly to sales in 2024 and meaningfully in 2025 and beyond. - Company expects HIV sales to be roughly flat in 2025 due to Medicare Part D redesign impacts but overall business to grow. - Growth momentum is expected with upcoming milestones and new product launches planned. - No detailed data on specific order backlog or pending orders disclosed in the transcript.